Imigran Tablets 50mg
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Imigran Tablets 50mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
50mg sumatriptan base as the succinate salt.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet
50 mg tablet: Pink, film-coated, capsule-shaped, biconvex tablet (nominal dimensions: 12 mm x 6.5 mm), engraved “GX ES3” on one face and plain on the other face
or “50” on one face and plain on the other face.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Imigran tablets are indicated for the acute relief of migraine attacks, with or without aura. Imigran should only be used where there is a clear diagnosis of migraine.
4.2 Posology and method of administration
Adults
Imigran is indicated for the acute intermittent treatment of migraine. It should not be used prophylactically.
It is advisable that Imigran be given as early as possible after the onset of migraine attack but it is equally effective at whatever stage of the attack it is administered.
The recommended dose of oral Imigran is a single 50mg tablet. Some patients may require 100mg.
If the patient has responded to the first dose but the symptoms recur a second dose may be given in the next 24 hours provided that there is a minimum interval of two hours between the two doses. No more than 300mg should be taken in any 24 hour period.
Patients who do not respond to the prescribed dose of Imigran should not take a second dose for the same attack. In these cases the attack can be treated with paracetamol, acetylsalicylic acid, or non-steroidal anti-inflammatory drugs. Imigran may be taken for subsequent attacks.
Imigran is recommended as monotherapy for the acute treatment of migraine and should not be given concomitantly with ergotamine or derivatives of ergotamine (including methysergide) (see section 4.3).
The tablets should be swallowed whole with water.
Paediatric population
The efficacy and safety of Imigran in children aged less than 10 years have not been established. No clinical data are available in this age group.
The efficacy and safety of Imigran in children 10 to 17 years of age have not been demonstrated in the clinical trials performed in this age group. Therefore the use of Imigran in children 10 to 17 years of age is not recommended (see section 5.1).
Elderly (Over 65 years of age)
Experience of the use of Imigran in patients aged over 65 years is limited. The pharmacokinetics do not differ significantly from a younger population but until further clinical data are available, the use of Imigran in patients aged over 65 years is not recommended.
4.3 Contraindications
Hypersensitivity to sumatriptan or to any of the excipients listed in section 6.1.
Sumatriptan should not be given to patients who have had myocardial infarction or have ischaemic heart disease, coronary vasospasm (Prinzmetal’s angina), peripheral vascular disease or patients who have symptoms or sign consistent with ischaemic heart disease.
Sumatriptan should not be administered to patients with a history of cerebovascular accident (CVA) or transient ischaemic attack (TIA).
Sumatriptan should not be administered to patients with severe hepatic impairment.
The use of sumatriptan in patients with moderate and severe hypertension and mild uncontrolled hypertension is contraindicated.
The concomitant administration of ergotamine or derivatives of ergotamine (including methysergide) or any triptan/5-hydroxytryptaminei (5-HTj) receptor agonist with sumatriptan is contraindicated. (see section 4.5)
Concurrent administration of monoamine oxidase inhibitors and sumatriptan is contraindicated.
Imigran Tablets must not be used within two weeks of discontinuation of therapy with monoamine oxidase inhibitors.
4.4 Special warnings and precautions for use
Imigran should only be used where there is a clear diagnosis of migraine.
Sumatriptan is not indicated for use in the management of hemiplegic, basilar or ophthalmoplegic migraine.
The recommended doses of sumatriptan should not be exceeded. As with other migraine therapies, before treating headaches in patients not previously diagnosed as migraineurs, and in migraineurs who present atypical symptoms, care should be taken to exclude other potentially serious neurological conditions.
It should be noted that migraineurs may be at risk of certain cerebrovascular events (e.g. cerebrovascular accident, transient ischaemic attack).
Following administration, sumatriptan can be associated with transient symptoms including chest pain and tightness which may be intense and involve the throat (see section 4.8). Where such symptoms are thought to indicate ischaemic heart disease, no further doses of sumatriptan should be given and appropriate evaluation should be carried out.
Sumatriptan should not be given to patients with risk factors for ischaemic heart disease, including those patients who are heavy smokers or users of nicotine substitution therapies, without prior cardiovascular evaluation (see section 4.3). Special consideration should be given to postmenopausal women and males over 40 with these risk factors. These evaluations however, may not identify every patient who has cardiac disease and, in very rare cases, serious cardiac events have occurred in patients without underlying cardiovascular disease.
Sumatriptan should be administered with caution to patients with mild controlled hypertension, since transient increases in blood pressure and peripheral vascular resistance have been observed in a small proportion of patients (see section 4.3).
There have been rare post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. Serotonin syndrome has been reported following concomitant treatment with triptans and serotonin noradrenaline reuptake inhibitors (SNRIs).
If concomitant treatment with sumatriptan and an SSRI/SNRI is clinically warranted, appropriate observation of the patient is advised (see section 4.5).
Sumatriptan should be administered with caution to patients with conditions which may affect significantly the absorption, metabolism or excretion of drugs, e.g. impaired hepatic or renal function. A 50mg dose should be considered in patients with hepatic impairment.
Sumatriptan should be used with caution in patients with a history of seizures or other risk factors which lower the seizure threshold, as seizures have been reported in association with sumatriptan (see section 4.8).
Patients with known hypersensitivity to sulphonamides may exhibit an allergic reaction following administration of sumatriptan. Reactions may range from cutaneous hypersensitivity to anaphylaxis. Evidence of cross-sensitivity is limited, however, caution should be exercised before using sumatriptan in these patients.
Undesirable effects may be more common during concomitant use of triptans and herbal preparations containing St John’s Wort (Hypericum perforatum).
Prolonged use of any type of painkiller for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained and treatment should be discontinued. The diagnosis of medication overuse headache (MOH) should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of headache medications.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine as it contains lactose.
4.5 Interaction with other medicinal products and other forms of Interaction
Studies in healthy subjects show that sumatriptan does not interact with propranolol, flunarizine, pizotifen or alcohol.
There are limited data on an interaction with preparations containing ergotamine or another triptan/5-HT1 receptor agonist. The increased risk of coronary vasospasm is a theoretical possibility and concomitant administration is contraindicated (see section 4.3).
The period of time that should elapse between the use of sumatriptan and ergotamine-containing preparations or another triptan/5-HT1 receptor agonist is not known. This will also depend on the doses and types of products used. The effects may be additive. It is advised to wait at least 24 hours following the use of ergotamine-containing preparations or another triptan/5-HT1 receptor agonist before administering sumatriptan. Conversely, it is advised to wait at least 6 hours following use of sumatriptan before administering an ergotamine-containing product and at least 24 hours before administering another triptan/5-HT1 receptor agonist.
An interaction may occur between sumatriptan and monoamine oxidase inhibitors (MAOIs) and concomitant administration is contraindicated (see section 4.3).
There have been rare post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the use of SSRIs and sumatriptan. Serotonin syndrome has also been reported following concomitant treatment with triptans and SNRIs (see section 4.4).
4.6 Fertility, pregnancy and lactation
Pregnancy
Post-marketing data from the use of sumatriptan during the first trimester in over 1,000 women are available. Although these data contain insufficient information to draw definitive conclusions, they do not point to an increased risk of congenital defects. Experience with the use of sumatriptan in the second and third trimester is limited.
Evaluation of experimental animal studies does not indicate direct teratogenic effects or harmful effects on peri- and postnatal development. However, embryofoetal viability might be affected in the rabbit (see section 5.3). Administration of sumatriptan should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.
Lactation
It has been demonstrated that following subcutaneous administration, sumatriptan is excreted into breast milk. Infant exposure can be minimised by avoiding breast feeding for 12 hours after treatment, during which time any breast milk expressed should be discarded.
4.7 Effect on Ability to Drive and Use Machines
No studies on the effects on the ability to drive and use machines have been performed. Drowsiness may occur as a result of migraine or its treatment with sumatriptan. This may influence the ability to drive and to operate machinery.
4.8 Undesirable effects
Adverse events are listed below by system organ class and frequency [4].
Frequencies are defined as: very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/10,000, <1/1000), very rare (<1/10,000), not known (cannot be estimated from the available data). Some of the symptoms reported as undesirable effects may be associated symptoms of migraine.
Clinical Trial Data
Nervous System Disorders
Dizziness, drowsiness, sensory disturbance including paraesthesia and hypoaesthesia.
Common:
Vascular Disorders
Common: Transient increases in blood pressure arising soon after
treatment. Flushing.
Respiratory, Thoracic and Mediastinal Disorders
Common Dyspnoea.
Gastrointestinal Disorders
Common: Nausea and vomiting occurred in some patients but it is
unclear if this is related to sumatriptan or the underlying condition.
Musculoskeletal and Connective Tissue Disorders
Common: Sensations of heaviness (usually transient and may
be intense and can affect any part of the body including the chest and throat).
Myalgia.
General Disorders and Administration Site Conditions
Common: Pain, sensations of heat or cold, pressure or tightness
(these events are usually transient and may be intense and can affect any part of the body including the chest and throat).
Feelings of weakness, fatigue (both events are mostly mild to moderate in intensity and transient).
Investigations
Very rare: Minor disturbances in liver function tests have
occasionally been observed.
Post-Marketing Data
Immune System Disorders
Not known: Hypersensitivity reactions ranging from cutaneous
hypersensitivity to anaphylaxis.
Nervous System Disorders
Not known: Seizures, although some have occurred in patients
with either a history of seizures or concurrent conditions predisposing to seizures there are also reports in patients where no such predisposing factors are apparent.
Tremor, dystonia, nystagmus, scotoma.
Eye Disorders
Not known: Flickering, diplopia, reduced vision. Loss of vision
including reports of permanent defects. However, visual disorders may also occur during a migraine attack itself.
Cardiac Disorders
Not known: Bradycardia, tachycardia, palpitations, cardiac
arrhythmias, transient ischaemic ECG changes, coronary artery vasospasm, angina, myocardial infarction (see sections 4.3 and 4.4).
Vascular Disorders
Not known: Hypotension, Raynaud’s phenomenon.
Gastrointestinal Disorders
Not known: Ischaemic colitis
Diarrhoea.
Musculoskeletal, Connective Tissue and Bone Disorders
Not known: Neck stiffness.
Arthralgia.
Psychiatric disorders
Not known: Anxiety.
Skin and subcutaneous tissue disorders
Not known: Hyperhidrosis.
4.9 Overdose
Doses in excess of 400mg orally were not associated with side effects other than those mentioned.
If overdosage occurs, the patient should be monitored for at least ten hours and standard supportive treatment applied as required.
It is unknown what effect haemodialysis or peritoneal dialysis has on the plasma concentrations of Imigran.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Analgesics: Selective 5-HTi receptor agonists. ATC code: N02CC01
Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine1 (5HT1D) receptor agonist with no effect on other 5HT receptor (5-HT2-5-HT7) subtypes. The vascular 5-HT1D receptor is found predominantly in cranial blood vessels and mediates vasoconstriction. In animals, sumatriptan selectively constricts the carotid arterial circulation but does not alter cerebral blood flow. The carotid arterial circulation supplies blood to the extracranial and intracranial tissues such as the meninges and dilatation of and/or oedema formation in these vessels is thought to be the underlying mechanism of migraine in man.
In addition, evidence from animal studies suggests that sumatriptan inhibits trigeminal nerve activity. Both these actions (cranial vasoconstriction and inhibition of trigeminal nerve activity) may contribute to the anti-migraine action of sumatriptan in humans.
Sumatriptan remains effective in treating menstrual migraine i.e. migraine without aura that occurs between 3 days prior and up to 5 days post onset of menstruation. Sumatriptan should be taken as soon as possible in an attack.
Clinical response begins around 30 minutes following a 100 mg oral dose.
Although the recommended dose of oral sumatriptan is 50 mg, migraine attacks vary in severity both within and between patients. Doses of 25-100 mg have shown greater efficacy than placebo in clinical trials, but 25 mg is statistically significantly less effective than 50 and 100 mg.
A number of placebo-controlled clinical studies assessed the safety and efficacy of oral sumatriptan standard tablets in over 650 child and adolescent migraineurs aged 10 - 17 years. These studies failed to demonstrate a statistically significant difference in headache relief at 2 hours between placebo and any sumatriptan dose. The undesirable effects profile of oral sumatriptan in children and adolescents aged 10 - 17 years was similar to that reported from studies in the adult population.
5.2 Pharmacokinetic properties
Following oral administration, Sumatriptan is rapidly absorbed, 70% of maximum concentration occurring at 45 minutes. After 100mg dose, the maximum plasma concentration is 54ng/ml. Mean absolute oral bioavailability is 14% partly due to presystemic metabolism and partly due to incomplete absorption. The elimination phase half-life is approximately 2 hours, although there is an indication of a longer terminal phase. Plasma protein binding is low (14-21%), mean volume of distribution is 170 litres. Mean total plasma clearance is approximately 1160ml/min and the mean renal plasma clearance is approximately 260ml/min. Non-renal clearance accounts for about 80% of the total clearance. Sumatriptan is eliminated primarily by oxidative metabolism mediated by monoamine oxidase A. The major metabolite, the indole acetic acid analogue of Sumatriptan is mainly excreted in the urine, where it is present as a free acid and the glucuronide conjugate. It has no known 5HT1 or 5HT2 activity. Minor metabolites have not been identified. The pharmacokinetics of oral Sumatriptan do not appear to be significantly affected by migraine attacks.
In a pilot study, no significant differences were found in the pharmacokinetic parameters between the elderly and young healthy volunteers.
5.3 Preclinical Safety Data
Sumatriptan was devoid of genotoxic and carcinogenic activity in in-vitro systems and animal studies.
In a rat fertility study oral doses of sumatriptan resulting in plasma levels approximately 200 times those seen in man after a 100 mg oral dose were associated with a reduction in the success of insemination.
This effect did not occur during a subcutaneous study where maximum plasma levels achieved approximately 150 times those in man by the oral route.
In rabbits embryolethality, without marked teratogenic defects, was seen. The relevance for humans of these findings is unknown.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose
Microcrystalline cellulose Croscarmellose sodium Magnesium stearate Methylhydroxypropylcellulose Titanium dioxide Triacetin Iron oxide
6.2 Incompatibilities
None stated.
6.3 Shelf life
36 months.
6.4 Special precautions for storage
Store below 30°C
6.5 Nature and contents of container
Aluminium double foil blister packs in a cardboard carton, containing either 2, 3, 6, 12, 18 or 24 tablets.
6.6 Instruction for use, handling and disposal
None stated.
7 MARKETING AUTHORISATION HOLDER
Glaxo Wellcome UK Ltd. trading as GlaxoSmithKline UK.
Stockley Park West
Uxbridge
Middlesex. UB11 1BT
8. MARKETING AUTHORISATION NUMBER(S)
PL 10949/0222
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
29/12/2005
10 DATE OF REVISION OF THE TEXT
28/04/2015